A first study was performed to assess the safety and efficacy of low dose lymphoblastoid IFNα and Tα1 in patients with chronic hepatitis B, either naïve or non-responsive to standard IFN-α2b (48). The gene discussed is IFNA2; the disease is chronic hepatitis B virus infection.